Signifor LAR

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical*	❑ *Home*	❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital*	❑ *Office*	❑ *Pharmacy*

What is the ICD-10 code? _____

Exception Criteria Questions:

A. Is the product being requested for the treatment of acromegaly?
❑ Yes ❑ No *If No, skip to Clinical Criteria Questions*

B. The preferred products for your patient's health plan are Somatuline Depot and Sandostatin LAR. Can the patient's treatment be switched to Somatuline Depot or Sandostatin LAR?
❑ Yes *Please obtain Form for preferred product and submit for corresponding PA.*
❑ No

C. Does the patient have a documented inadequate response or intolerable adverse event to treatment with any of the preferred products (Somatuline Depot and Sandostatin LAR)? ***ACTION REQUIRED: If Yes, please attach supporting chart note(s).*** ❑ Yes ❑ No

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

 Signifor LAR MR SGM 2096-A – 08/2023.

Criteria Questions:

1. What is the diagnosis?

❒ Acromegaly (*If checked, go to 2*)

❒ Cushing's disease (*If checked, go to 7*)

❒ Other, please specify. _____ (*If checked, no further questions*)

2. Is the patient currently on therapy with the requested medication?
❒ Yes, *Continue to 6*
❒ No, *Continue to 3*

3. How does the patient's pretreatment IGF-1 (insulin-like growth factor 1) level compare to the laboratory's reference normal range based on age and/or gender? ***ACTION REQUIRED***: Attach a laboratory report or chart note(s) with pretreatment IGF-level and reference normal range.
❒ IGF-1 level is higher than the laboratory's normal range ***ACTION REQUIRED***: Submit supporting documentation (*If checked, go to 4*)
❒ IGF-1 level is lower than the laboratory's normal range ***ACTION REQUIRED***: Submit supporting documentation (*If checked, go to 4*)
❒ IGF-1 level falls within the laboratory's normal range ***ACTION REQUIRED***: Submit supporting documentation (*If checked, go to 4*)
4. Has the patient had an inadequate or partial response to surgery? ***ACTION REQUIRED***: If yes, attach supporting chart note(s) indicating an inadequate or partial response to surgery.
❒ Yes, *No Further Questions*
❒ No, *Continue to 5*

5. Is there a clinical reason why the patient has not had surgery? ***ACTION REQUIRED***: If yes, attach supporting chart note(s) indicating a clinical reason for not having surgery.
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

6. How has the patient's IGF-1 (insulin-like growth factor 1) level changed since initiation of therapy? ***ACTION REQUIRED***: If decreased or normalized, attach laboratory report indicating normal current IGF-1 levels or chart notes indicating that the patient's IGF-1 level has decreased or normalized since initiation of therapy.

❒ Increased (*If checked, no further questions*)
❒ Decreased or normalized ***ACTION REQUIRED***: Submit supporting documentation (*If checked, no further questions*)

❒ No change (If checked, *no further questions*)

7. Is the patient currently receiving treatment with the requested medication?
❒ Yes, *Continue to 11*
❒ No, *Continue to 8*

8. Does the patient have a pretreatment cortisol level as indicated by one of the following tests: i.) Urinary free cortisol (UFC) level, ii.) Late-night salivary cortisol, iii.) 1 mg overnight dexamethasone suppression test (DST), iv.) Longer, low dose DST (2mg per day for 48 hours)? ***ACTION REQUIRED***: If yes, attach pretreatment cortisol level as measured by one of the following tests: urinary free cortisol (UFC) level; late-night salivary cortisol; 1mg overnight dexamethasone suppression test (DST); longer, low dose DST (2mg per day for 48 hours).

❒ Yes ***ACTION REQUIRED***: Submit supporting documentation (*If checked, go to 9*)

❒ No (*If checked, go to 9*)

❒ Unknown (*If checked, go to 9*)
9. Did the patient have surgery that was not curative? ***ACTION REQUIRED***: If yes, attach supporting chart note(s) indicating that the patient's surgery was not curative.

❒ Yes, *No Further Questions*
❒ No, *Continue to 10*

10. Is the patient a candidate for surgery? ***ACTION REQUIRED***: If no, attach supporting chart note(s) indicating that surgery is not an option for the patient.
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

11. Has the patient experienced a reduction in cortisol level since the start of therapy with the requested medication as indicated by one of the following tests: i.) Urinary free cortisol (UFC), ii.) Late-night salivary cortisol, iii.) 1 mg overnight dexamethasone suppression test (DST), iv.) Longer, low dose DST (2mg per day for 48 hours)? ***ACTION REQUIRED***: If yes, laboratory report indicating current cortisol level has decreased from baseline as measured by one of the following tests: urinary free cortisol (UFC) level; late-night salivary cortisol; 1mg overnight dexamethasone suppression test (DST); longer, low dose DST (2mg per day for 48 hours) (if applicable).

❒ Yes, ***ACTION REQUIRED***: Submit supporting documentation (*If checked, no further questions*)

❒ No (*If checked, go to 12*)

❒ Unknown (*If checked, go to 12*)

12. Has the patient had an improvement of signs and symptoms of the disease since the start of therapy with the requested medication?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

Step Therapy Override: Complete if Applicable for the state of Maryland.	Please Circle	
Is the requested drug being used to treat stage four advanced metastatic cancer?	Yes	No
Is the requested drug's use consistent with the FDA-approved indication or the National Comprehensive Cancer Network Drugs & Biologics Compendium indication for the treatment of stage four advanced metastatic cancer and is supported by peer-reviewed medical literature?	Yes	No
Is the requested drug being used for an FDA-approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?	Yes	No
Does the prescribed quantity fall within the manufacturer's published dosing guidelines or within dosing guidelines found in the compendia of current literature (examples: package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?	Yes	No
Do patient chart notes document the requested drug was ordered with a paid claim at the pharmacy, the pharmacy filled the prescription and delivered to the patient or other documentation that the requested drug was prescribed for the patient in the last 180 days?	Yes	No
Has the prescriber provided proof documented in the patient chart notes that in their opinion the requested drug is effective for the patient's condition?	Yes	No

Step Therapy Override: Complete if Applicable for the state of Virginia.	Please Circle	
Is the requested drug being used for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)?	Yes	No
Does the prescribed dose and quantity fall within the FDA-approved labeling or within dosing guidelines found in the compendia of current literature?	Yes	No
Is the request for a brand drug that has an AB-rated generic equivalent or interchangeable biological product available?	Yes	No
Has the patient had a trial and failure of the AB-rated generic equivalent or interchangeable biological product due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient?	Yes	No
Is the preferred drug contraindicated?	Yes	No
Is the preferred drug expected to be ineffective based on the known clinical characteristics of the patient and the prescription drug regimen?	Yes	No
Has the patient tried the preferred drug while on their current or previous health benefit plan and it was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?	Yes	No
Is the patient currently receiving a positive therapeutic outcome with the requested drug for their medical condition?	Yes	No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com